Levels of macrophage migration inhibitory factor and glucocorticoids in chronic wound patients and their potential interactions with impaired wound endothelial progenitor cell migration

Wound Repair and Regeneration

Volumn 20, Issue 5, 2012, Pages 707-714

  Grieb, Gerrit ^a   Simons, David ^a,b   Eckert, Lena ^a   Hemmrich, Melanie ^a   Steffens, Guy ^a   Bernhagen, Jürgen ^a   Pallua, Norbert ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; MACROPHAGE MIGRATION INHIBITION FACTOR;

ACUTE WOUND; ADULT; ARTICLE; CELL MIGRATION; CHRONIC WOUND; CLINICAL ARTICLE; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WOUND; WOUND FLUID; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CXCL12; CHEMOTAXIS; CHRONIC DISEASE; COHORT STUDIES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELLS; WOUND HEALING; YOUNG ADULT;

EID: 84866503606     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2012.00817.x     Document Type: Article

References (37)

1. Ulrich D, Lichtenegger F, Unglaub F, Smeets R, Pallua N,. Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro. Plast Reconstr Surg 2005; 116: 539-545.
2. Lazarus GS, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, Robson MC,. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994; 130: 489-493.
3. Mathieu D,. Hyperbaric oxygen therapy in the management of non-healing wounds. In:, Bakker DJ, Cramer FS, editors. Hyperbaric surgery. Flagstaff, AZ: Best Publishing Company, 2002: 317-339.
4. Chaby G, Senet P, Vaneau M, Martel P, Guillaume JC, Meaume S, Teot L, Debure C, Dompmartin A, Bachelet H, Carsin H, Matz V, Richard JL, Rochet JM, Sales-Aussias N, Zagnoli A, Denis C, Guillot B, Chosidow O,. Dressings for acute and chronic wounds: a systematic review. Arch Dermatol 2007; 143: 1297-1304.
5. Ubbink DT, Westerbos SJ, Nelson EA, Vermeulen H,. A systematic review of topical negative pressure therapy for acute and chronic wounds [see comment]. Br J Surg 2008; 95: 685-692.
6. Diegelmann RF, Evans MC,. Wound healing: an overview of acute, fibrotic and delayed healing. Frontiers Biosci 2004; 9: 283-289.
7. Enoch S, Grey JE, Harding KG,. Recent advances and emerging treatments. BMJ 2006; 332: 962-965.
8. Agren MS, Eaglstein WH, Ferguson MW, Harding KG, Moore K, Saarialho-Kere UK, Schultz GS,. Causes and effects of the chronic inflammation in venous leg ulcers. Acta Derm Venereol Suppl (Stockh) 2000; 210: 3-17.
9. Wysocki AB, Kusakabe AO, Chang S, Tuan TL,. Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. Wound Repair Regen 1999; 7: 154-165.
10. Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT Jr, Hobson RW 2nd, Duran WN, Pappas PJ,. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 2001; 34: 930-938.
11. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G,. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep Reg 1999; 7: 442-452.
12. Tarlton JF, Bailey AJ, Crawford E, Jones D, Moore K, Harding KD,. Prognostic value of markers of collagen remodeling in venous ulcers. Wound Rep Reg 1999; 7: 347-355.
13. Stetler-Stevenson WG,. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-1241.
14. Gilliver SC, Emmerson E, Bernhagen J, Hardman MJ,. MIF: a key player in cutaneous biology and wound healing. Exp Dermatol 2011; 20: 1-6.
15. Calandra T, Roger T,. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3: 791-800.
16. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C,. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13: 587-596.
17. Schober A, Bernhagen J, Weber C,. Chemokine-like functions of MIF in atherosclerosis. J Mol Med 2008; 86: 761-770.
18. Zernecke A, Bernhagen J, Weber C,. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008; 117: 1594-1602.
19. Beishuizen A, Thijs LG, Haanen C, Vermes I,. Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 2001; 86: 2811-2816.
20. Grieb G, Simons D, Piatkowski A, Bernhagen J, Steffens G, Pallua N,. Macrophage migration inhibitory factor-A potential diagnostic tool in severe burn injuries? Burns 2010; 36: 335-342.
21. Simons D, Grieb G, Hristov M, Pallua N, Weber C, Bernhagen J, Steffens G,. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med 2011; 15: 668-678.
22. Grieb G, Piatkowski A, Simons D, Hörmann N, Dewor M, Steffens G, Bernhagen J, Pallua N,. Macrophage migration inhibitory factor is a potential inducer of endothelial progenitor cell mobilization after flap operation. Surgery 2012; 151: 268-277.
23. Zhao Y, Shimizu T, Nishihira J, Koyama Y, Kushibiki T, Honda A, Watanabe H, Abe R, Tabata Y, Shimizu H,. Tissue regeneration using macrophage migration inhibitory factor-impregnated gelatin microbeads in cutaneous wounds. Am J Pathol 2005; 167: 1519-1529.
24. Dewor M, Steffens G, Krohn R, Weber C, Baron J, Bernhagen J,. Macrophage migration inhibitory factor (MIF) promotes fibroblast migration in scratch-wounded monolayers in vitro. FEBS Lett 2007; 581: 4734-4742.
25. Ashcroft GS, Mills SJ, Lei K, Gibbons L, Jeong MJ, Taniguchi M, Burow M, Horan MA, Wahl SM, Nakayama T,. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest 2003; 111: 1309-1318.
26. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J,. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett 2003; 551: 78-86.
27. Grieb G, Groger A, Piatkowski A, Markowicz M, Steffens GC, Pallua N,. Tissue substitutes with improved angiogenic capabilities: an in vitro investigation with endothelial cells and endothelial progenitor cells. Cells Tissues Organs 2010; 191: 96-104.
28. Grieb G, Merk M, Bernhagen J, Bucala R,. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect 2010; 23: 257-264.
29. Flaster H, Bernhagen J, Calandra T, Bucala R,. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007; 21: 1267-1280.
30. Clyne B, Olshaker JS,. The C-reactive protein. J Emerg Med 1999; 17: 1019-1025.
31. Kirwan JR, Balint G, Szebenyi B,. Anniversary: 50 years of glucocorticoid treatment in rheumatoid arthritis [see comment]. Rheumatology 1999; 38: 100-102.
32. Rhen T, Cidlowski JA,. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
33. Aeberli D, Leech M, Morand EF,. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology 2006; 45: 937-943.
34. Ahonen J, Jiborn H,. Hormone influence on wound healing. In:, Hunt TK, editor. Wound healing and wound infection. Theory and surgical practice. New York: Appleton-Century-Crofts, 1977: 99-105.
35. Anstead GM,. Steroids, retinoids, and wound healing. Advanc Wound Care 1998; 11: 277-285.
36. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R,. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia [erratum appears in Nature 1995 Nov 23;378(6555):419]. Nature 1993; 365: 756-759.
37. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WF, Zeiher AM, Dimmeler S,. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39: 733-742.